GlassScriptPhysician profile
Richard A Rison
NPI 1497730709
$10,643.13
in general payments reported to CMS, 2019-2025
56 companies · $2,672 in 2025
The $2,672 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $190 · 2021: $741 · 2022: $1,085 · 2023: $2,311 · 2024: $3,491 · 2025: $2,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,474.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,471.63 | 2019-2025 | |
| Abbvie INC. | $1,333.17 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Ucb, INC. | $1,030.72 | 2021-2025 | Briviact, Rystiggo, Fintepla |
| Lundbeck LLC | $747.55 | 2022-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $497.10 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Mdd US Operations, LLC | $459.83 | 2022-2025 | Gocovri, Gocovri |
| Pfizer INC. | $422.16 | 2023-2025 | |
| Biogen, INC. | $350.92 | 2021-2025 | Vumerity, Leqembi, Tysabri |
| Teva Pharmaceuticals USA, INC. | $347.79 | 2022-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $325.29 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $299.64 | 2023-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $287.26 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Celgene Corporation | $276.75 | 2023-2025 | Zeposia |
| Acadia Pharmaceuticals INC | $244.40 | 2023-2025 | Nuplazid, Daybue |
| Neurocrine Biosciences, INC. | $224.16 | 2021-2024 | Ingrezza |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.